Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Tak source : Www.biospace.com save search
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
NBIX | News M | $140.11 4.83% 4.6% 1.6M
|
Health Technology
|
| O: 5.43%
H: 0.0%
C: 0.0%
nbi-1065 positive for
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.84%
H: 0.24%
C: -0.14%
adzynma japan takeda approval injection
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
iclusig fda drug takeda approval application
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079 positive topline potential results study
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: 0.2%
vaccine dengue tak-003 qdenga
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -3.56%
H: 2.91%
C: -3.34%
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: -0.4%
H: 0.23%
C: -0.46%
MGNX | $16.23 5.32% 5.05% 650K
|
Health Technology
|
| O: -5.25%
H: 2.94%
C: 2.18%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
financial
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.07%
H: 0.46%
C: 0.42%
fda first treatment
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
Published: 2024-02-01 (Crawled : 09:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -1.98%
fy2023 management momentum growth
Takeda Announces Chief Financial Officer Succession
Published: 2024-02-01 (Crawled : 09:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -1.98%
financial
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.38%
H: 0.78%
C: 0.78%
hyqvia approved therapy
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
Takeda Named Global Top Employer for Seventh Consecutive Year
Published: 2024-01-18 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.13%
H: 0.27%
C: 0.2%
year global
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.27%
H: 0.61%
C: -0.2%
ohb-607 license group oak agreement therapy
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 2.05%
H: 0.29%
C: 0.0%
livtencity approval cytomegalovirus treatment china
Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA Treatment for Rare form of Emphysema
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.36%
H: 0.14%
C: -1.01%
rare services glassia contract treatment blood
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.64%
H: 0.21%
C: -1.79%
hyqvia chmp positive therapy
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
Published: 2023-11-27 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.42%
C: 0.21%
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.07%
H: 0.57%
C: 0.0%
cancer treatment
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -1.09%
H: 1.03%
C: 0.91%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: 2.22%
H: 0.6%
C: -9.4%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.28%
H: 1.0%
C: -0.46%
presentation meeting
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.